Company CG Oncology, Inc.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Number of employees: 61